Zosano Pharma Corporation (ZSAN)
NASDAQ: ZSAN
· Real-Time Price · USD
0.56
0.00 (0.43%)
At close: Apr 24, 2025, 3:47 PM
Company Description
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.
Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine.
The company was founded in 2006 and is headquartered in Fremont, California.
On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Zosano Pharma Corporation
| Country | United States |
| IPO Date | Jan 27, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Steven Lo |
Contact Details
Address: 34790 Ardentech Ct Fremont, CALIFORNIA United States | |
| Website | https://www.zosanopharma.com |
Stock Details
| Ticker Symbol | ZSAN |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001587221 |
| CUSIP Number | 98979H202 |
| ISIN Number | US98979H2022 |
| Employer ID | 45-4488360 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2022 | 25-NSE | Filing |
| Jun 07, 2022 | 4 | Filing |
| Jun 07, 2022 | 4 | Filing |
| Jun 03, 2022 | 8-K | Current Report |
| Jun 02, 2022 | 8-K | Current Report |
| May 18, 2022 | SC 13G | Statement of acquisition of beneficial ownership b... |
| May 18, 2022 | 8-K | Current Report |
| May 13, 2022 | 10-Q | Quarterly Report |
| May 13, 2022 | 8-K | Current Report |
| May 05, 2022 | 8-K | Current Report |